EKSO BIONICS HOLDINGS INC (EKSO)
US2826443010 - Common Stock
Taking everything into account, EKSO scores 2 out of 10 in our fundamental rating. EKSO was compared to 187 industry peers in the Health Care Equipment & Supplies industry. EKSO may be in some trouble as it scores bad on both profitability and health. EKSO is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year EKSO has reported negative net income.
EKSO had a negative operating cash flow in the past year.
EKSO had negative earnings in each of the past 5 years.
In the past 5 years EKSO always reported negative operating cash flow.
1.2 Ratios
EKSO has a worse Return On Assets (-38.11%) than 60.22% of its industry peers.
EKSO's Return On Equity of -74.86% is on the low side compared to the rest of the industry. EKSO is outperformed by 61.29% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -38.11% | ||
| ROE | -74.86% | ||
| ROIC | N/A |
ROA(3y)-37.12%
ROA(5y)-48.71%
ROE(3y)-69.61%
ROE(5y)-148.91%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
EKSO has a Gross Margin (51.84%) which is in line with its industry peers.
In the last couple of years the Gross Margin of EKSO has grown nicely.
The Profit Margin and Operating Margin are not available for EKSO so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 51.84% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.54%
GM growth 5Y5.48%
2. Health
2.1 Basic Checks
EKSO does not have a ROIC to compare to the WACC, probably because it is not profitable.
EKSO has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, EKSO has more shares outstanding
The debt/assets ratio for EKSO is higher compared to a year ago.
2.2 Solvency
EKSO has an Altman-Z score of -11.35. This is a bad value and indicates that EKSO is not financially healthy and even has some risk of bankruptcy.
EKSO has a Altman-Z score of -11.35. This is amonst the worse of the industry: EKSO underperforms 81.18% of its industry peers.
A Debt/Equity ratio of 0.28 indicates that EKSO is not too dependend on debt financing.
EKSO has a Debt to Equity ratio (0.28) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.28 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -11.35 |
ROIC/WACCN/A
WACC8.31%
2.3 Liquidity
EKSO has a Current Ratio of 2.81. This indicates that EKSO is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 2.81, EKSO is in line with its industry, outperforming 51.61% of the companies in the same industry.
EKSO has a Quick Ratio of 2.14. This indicates that EKSO is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of EKSO (2.14) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.81 | ||
| Quick Ratio | 2.14 |
3. Growth
3.1 Past
EKSO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 41.96%, which is quite impressive.
EKSO shows a small growth in Revenue. In the last year, the Revenue has grown by 4.13%.
The Revenue has been growing by 10.04% on average over the past years. This is quite good.
EPS 1Y (TTM)41.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%58.33%
Revenue 1Y (TTM)4.13%
Revenue growth 3Y27.21%
Revenue growth 5Y10.04%
Sales Q2Q%-10.38%
3.2 Future
The Earnings Per Share is expected to grow by 26.38% on average over the next years. This is a very strong growth
Based on estimates for the next years, EKSO will show a quite strong growth in Revenue. The Revenue will grow by 18.30% on average per year.
EPS Next Y54.56%
EPS Next 2Y35.05%
EPS Next 3Y26.38%
EPS Next 5YN/A
Revenue Next Year-0.47%
Revenue Next 2Y17.47%
Revenue Next 3Y18.3%
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
EKSO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year EKSO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as EKSO's earnings are expected to grow with 26.38% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.05%
EPS Next 3Y26.38%
5. Dividend
5.1 Amount
EKSO does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
EKSO BIONICS HOLDINGS INC
NASDAQ:EKSO (1/8/2025, 8:00:01 PM)
After market: 0.6899 -0.01 (-1.46%)0.7001
-0.13 (-15.65%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners14.63%
Inst Owner Change0%
Ins Owners7.02%
Ins Owner Change0%
Market Cap15.40M
Analysts82.5
Price Target5.61 (701.31%)
Short Float %0.62%
Short Ratio0.95
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)4.3%
Min EPS beat(2)1.96%
Max EPS beat(2)6.63%
EPS beat(4)2
Avg EPS beat(4)-27.51%
Min EPS beat(4)-96.08%
Max EPS beat(4)6.63%
EPS beat(8)3
Avg EPS beat(8)-13.22%
EPS beat(12)6
Avg EPS beat(12)-9.24%
EPS beat(16)8
Avg EPS beat(16)-8.75%
Revenue beat(2)0
Avg Revenue beat(2)-16.61%
Min Revenue beat(2)-27.08%
Max Revenue beat(2)-6.14%
Revenue beat(4)0
Avg Revenue beat(4)-14.98%
Min Revenue beat(4)-27.08%
Max Revenue beat(4)-0.43%
Revenue beat(8)3
Avg Revenue beat(8)-2.6%
Revenue beat(12)4
Avg Revenue beat(12)-0.89%
Revenue beat(16)6
Avg Revenue beat(16)-2.73%
PT rev (1m)0%
PT rev (3m)-12%
EPS NQ rev (1m)0%
EPS NQ rev (3m)16.67%
EPS NY rev (1m)0%
EPS NY rev (3m)1.01%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-17.61%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-10.8%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.87 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.04 | ||
| P/tB | 1.58 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.65
EYN/A
EPS(NY)-0.19
Fwd EYN/A
FCF(TTM)-0.46
FCFYN/A
OCF(TTM)-0.45
OCFYN/A
SpS0.8
BVpS0.68
TBVpS0.44
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -38.11% | ||
| ROE | -74.86% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 51.84% | ||
| FCFM | N/A |
ROA(3y)-37.12%
ROA(5y)-48.71%
ROE(3y)-69.61%
ROE(5y)-148.91%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.54%
GM growth 5Y5.48%
F-Score5
Asset Turnover0.61
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.28 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 3.34% | ||
| Cap/Sales | 0.36% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.81 | ||
| Quick Ratio | 2.14 | ||
| Altman-Z | -11.35 |
F-Score5
WACC8.31%
ROIC/WACCN/A
Cap/Depr(3y)13.77%
Cap/Depr(5y)10%
Cap/Sales(3y)0.95%
Cap/Sales(5y)0.66%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)41.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%58.33%
EPS Next Y54.56%
EPS Next 2Y35.05%
EPS Next 3Y26.38%
EPS Next 5YN/A
Revenue 1Y (TTM)4.13%
Revenue growth 3Y27.21%
Revenue growth 5Y10.04%
Sales Q2Q%-10.38%
Revenue Next Year-0.47%
Revenue Next 2Y17.47%
Revenue Next 3Y18.3%
Revenue Next 5YN/A
EBIT growth 1Y27.46%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y29.45%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y29.2%
OCF growth 3YN/A
OCF growth 5YN/A